ClinicalTrials.gg
Drug

Catequentinib hydrochloride clinical trials

Also written Anlotinib Hydrochloride and AL3818.

A product of Anlotinib; its studies count on that page too.

studies test it
94
open now
20
in phase 3
12
first study started
2018

How each study uses catequentinib hydrochloride is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Get an email when these change. Save the catequentinib hydrochloride studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Get alerts for these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your alerts, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your alerts. Stop any time.

Approvals

The first approval found in each region, with its record

United States
Not in FDA's approval records
European Union
Not in EMA's list of EU-wide authorizations

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

Anlotinib
14
Anlotinib Hydrochloride Capsules
12
Anlotinib hydrochloride capsule
11

Development codes

AL3818
4

Other names

Anlotinib Hydrochloride
48

In one entry with another drug

Given together, or one or the other

Anlotinib Hydrochloride plus Docetaxel
4

Studies by the year they started

94 studies that test it; most in 2019 (22)

Studies that test catequentinib hydrochloride, by start year
YearStudies
20188
201922
202017
202118
20228
20239
20245
20251
20266

By phase

A phase 1/2 study counts in both.

Early Phase 1
2
Phase 1
10
Phase 2
63
Phase 3
12
Phase 4
5
No phase
7

What it is tested for

Each study’s main condition, where its own words name it, so a study counts once.

Who runs them

Industry 20 · Other 74

Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (20) · Sun Yat-sen University (6) · Peking Union Medical College Hospital (4) · Zhejiang Cancer Hospital (4) · The First Affiliated Hospital with Nanjing Medical University (3) · Henan Cancer Hospital (3) · Fudan University (2) · Cancer Institute and Hospital, Chinese Academy of Medical Sciences (2)

Often tested with

Tested in the same studies.

Penpulimab (11) · Benmelstobart (11) · Toripalimab (3) · Tislelizumab (2) · Sintilimab (2) · Aflutinib (1) · Partial Nephrectomy (1) · Epirubicin (1)

Related medicines

As reviewed, each with the page that says it.

Coming up

From the study records. Dates are the sponsors’ own estimates and often move.

Reaching primary completion within a year · 5, 1 in phase 3

Studies that test catequentinib hydrochloride, phase 3 first.

Studies

Open first, then newest update. How each study uses catequentinib hydrochloride is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 94

See all 94 studies that test catequentinib hydrochloride →

Given beside what is tested · 13 — catequentinib hydrochloride is usual care or a partner of the new treatment

What changed recently

From the registry's own updates since Oct 18, 2026.

Codes

What other systems call catequentinib hydrochloride · ClinicalTrials.gg INT015954

  • UNII (FDA) A3749M6582CATEQUENTINIB HYDROCHLORIDEOne source FDA
  • NCI Thesaurus C106428Catequentinib HydrochlorideOne source FDA

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.